Real‐World Data on Prognostic Factors for Overall Survival in EGFR Mutation‐Positive Advanced Non‐Small Cell Lung Cancer Patients Treated with First‐Line Gefitinib

Lignende værker

• Real-world analysis of survival outcomes in advanced EGFR-mutant NSCLC patients treated with platinum-pemetrexed after EGFR-TKI treatment failure
  af: Zong-Han Yao, et al.
  Udgivet: (2025-08-01)
• Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors
  af: Lee, Jih‐Hsiang, et al.
  Udgivet: (2019)
• Advanced non-small cell lung cancer in patients aged 45 years or younger: outcomes and prognostic factors
  af: Hsu, Chia-Lin, et al.
  Udgivet: (2012)
• Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R
  af: Gow, Chien-Hung, et al.
  Udgivet: (2005)
• Gefitinib or erlotinib in previously treated non–small‐cell lung cancer patients: a cohort study in Taiwan
  af: Chang, Chia‐Hao, et al.
  Udgivet: (2017)